ReproCELLorpTSE:4978 -0.80%57 Gross Margin % is 48.36% as of Mar. 2026, which is 12% above its 10-year median of 43.31. GuruFocus rates TSE:4978 with a GF Score™ of 57/100 and a GF Value™ of 円152.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, ReproCELLorp ranks worse than 64.48% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ReproCELLorp had a gross margin of 48.36% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ReproCELLorp Gross Margin % Related Terms
ReproCELLorp Gross Margin % Historical Data
* Premium members only.
The historical data trend for ReproCELLorp's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4978 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, ReproCELLorp's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ReproCELLorp Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ReproCELLorp's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ReproCELLorp's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ReproCELLorp (TSE:4978) has a Gross Margin % of 48.36% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on ReproCELLorp and its competitors. This is 12% above median its historical median of 43.31. Over the past decade, ReproCELLorp's Gross Margin % has ranged from 35.95 to 55.36. According to the industry distribution chart, ReproCELLorp ranks #472 out of 732 companies in the Biotechnology industry, placing it in the top 64.5%.
Is ReproCELLorp's Gross Margin % too high?
ReproCELLorp's current Gross Margin % of 48.36% is 12% above median its 10-year median of 43.31. Over the past 10 years, this metric has ranged from a low of 35.95 to a high of 55.36. The Biotechnology industry median Gross Margin % is 60.91. ReproCELLorp's value of 48.36% is 20.6% below this industry median. Based on the distribution chart, ReproCELLorp ranks #472 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ReproCELLorp has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ReproCELLorp's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ReproCELLorp ranks #472 out of 732 companies for Gross Margin %. This places ReproCELLorp in the lower half of its industry. The industry median Gross Margin % is 60.91. ReproCELLorp's value of 48.36% is 20.6% below this benchmark. Historically, ReproCELLorp's own Gross Margin % has ranged from 35.95 to 55.36 over the past decade. While the company's 10-year median is 43.31 vs. the industry median of 60.91, ReproCELLorp has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ReproCELLorp's current Gross Margin % of 48.36% is 20.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ReproCELLorp and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ReproCELLorp's current Gross Margin % is 48.36%, which is 12% above median its own 10-year median of 43.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ReproCELLorp stock overvalued right now?
Based on GuruFocus' analysis, ReproCELLorp (TSE:4978) is currently considered Modestly Undervalued. The stock's GF Value™ is 円152.61, compared to a current price of 円124.00 — trading 18.7% below its estimated fair value. The current Gross Margin % is 48.36%, which is 12% above median its 10-year median of 43.31 and 20.6% below the Biotechnology industry median of 60.91. ReproCELLorp's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ReproCELLorp (TSE:4978), the current Gross Margin % is 48.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ReproCELLorp (TSE:4978) Overvalued in 2026?
Based on GuruFocus' analysis, ReproCELLorp stock appears to be undervalued.
The current stock price of 円124.00 is trading 18.7% below its estimated GF Value™ of 円152.61.
GuruFocus considers ReproCELLorp to be Modestly Undervalued.
Key valuation signals for TSE:4978:
Gross Margin %: 48.36% (12% above median its 10-year median of 43.31)
GF Value™: 円152.61 vs. price of 円124.00 (18.7% below fair value)
Industry Position: 20.6% below the Biotechnology median (#472 of 732)
No single metric tells the full story. See the TSE:4978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ReproCELL Incorp is one of the leading stem cell research company in Japan. The company provides stem cell services, predictive drug discovery services, tissue services, and molecular services.
57GF Score
Get the complete analysis for TSE:4978
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4978 has been successfully added to your 
